Orion Pharma Limited

Nature of business The Company owns and operates a modern pharmaceuticals factory and produces and sells pharmaceuticals drugs and medicine.
Reason for IPO For construction of expansion project of Orion Pharma Limited at Valuka, Mymensingh in terms of the expansion of the existing product line along with the addition of new product lines.
Subscription open 06 Jan 2013
Subscription close 10 Jan 2013
Subscription close for NRB 06 Jan 2013 to 19 Jan 2013
Offer price Tk. 60.0
Face value per share Tk. 10.0
Market lot 100 units
Single lot price Tk. 6000.0
EPS Tk. 5.57 for the year ended December 31, 2011.
NAV Tk. 76.87 (considering revaluation reserve) as on December 31, 2011. Tk. 61.43 (without revaluation reserve) as on December 31, 2011.
Public offer 40,000,000
Major product Enliven (Imatinib Mesylate) capsule, Betacal (Atenolol plus amlodipine) tab, Vertex injection (Ceftriaxone sodium), Clognil plus (Clopidogrel+ Aspirin) tab, Pep (Zinc sulphate) Tab/Syrup, Deslor (Desloratadine) Tab/Syp, Axet (Cefuroxime) Tab/inj, Pedicef (Cefpodoxime) susp, Azalid (Azithromycin) Tab/Sus, Truso (Cefixime) Cap/sus.
Issue Manager ICB Capital Management Limited
Website www.orion-group.net

Share with friends